New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
12:43 EDTEBSEmergent BioSolutions secures U.S. commercial rights to influenza vaccine
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority.
News For EBS From The Last 14 Days
Check below for free stories on EBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
13:53 EDTEBSEmergent BioSolutions awarded contract valued at up to $29M with NIAID
Emergent BioSolutions has signed a contract with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a dry formulation of NuThrax, also known as AV7909, the company’s next generation anthrax vaccine candidate. This five-year contract, valued at up to $29M, provides funding for manufacturing and non-clinical activities through the preparation of an Investigational New Drug application to the U.S. Food and Drug Administration. The dry formulation of NuThrax is intended to increase stability of the vaccine candidate at ambient and higher temperatures, with the objective of eliminating the need for cold chain during shipping and storage. NuThrax is comprised of BioThrax in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909. The company is currently conducting a randomized, parallel-group, active-controlled, double-blind Phase 2 study designed to evaluate the safety and immunogenicity of NuThrax for post-exposure prophylaxis of anthrax infection using two- and three-dose immunization schedules and two dose levels. This development contract HHSN272201400038C will be administered through NIAID, part of the National Institutes of Health of the U.S. Department of Health and Human Services.
10:51 EDTEBSEmergent BioSolutions receives $29M HHS contract
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use